Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release
Background
The stimulator of interferon genes (STING) signaling pathway has been demonstrated to propagate the cancer-immunity cycle and remodel the tumor microenvironment and has emerged as an appealing target for cancer immunotherapy. Interest in ST…